sur Heidelberg Pharma AG (ETR:HPHA)
Heidelberg Pharma Announces Executive Board Change
Heidelberg Pharma AG, a clinical-stage biotech company, has announced an upcoming change in its executive board. Walter Miller, the current Chief Financial Officer (CFO), will step down at the end of April 2026. The Supervisory Board has appointed Peter Willinger as the new CFO, effective May 1, 2026. This transition occurs as the company advances its Phase I/IIa trial with its lead ADC candidate, HDP-101.
Peter Willinger brings over 20 years of CFO experience from notable biotech firms. His expertise includes IPOs, M&A activities, and managing finance-related departments. CEO Dr. Dongzhou Jeffery Liu and Chairman Karl Benedikt Biesinger expressed gratitude for Miller's service and confidence in Willinger's leadership.
Heidelberg Pharma's work on Amanitin-based ADC technology continues, focusing on multiple clinical developments. Willinger looks forward to driving the company's sustainable growth in this pivotal phase.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Heidelberg Pharma AG